Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2008-09-16
2008-09-16
Kemmerer, Elizabeth C. (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
C514S002600, C514S007600, C514S008100
Reexamination Certificate
active
10470924
ABSTRACT:
A bisphosphonate for the treatment of osteonecrosis and/or osteonecrosis dissecans. The drug may further be used to prevent the onset of osteonecrosis and/or osteonecrosis dissecans and any complications associated with both diseases.
REFERENCES:
patent: 5476865 (1995-12-01), Panetta et al.
patent: 5755809 (1998-05-01), Cohen et al.
patent: 5843678 (1998-12-01), Boyle
patent: 2004/0176327 (2004-09-01), Okuno et al.
patent: 97-416017/39 (1994-07-01), None
patent: WO 94/14455 (1994-07-01), None
patent: WO 95/28936 (1995-11-01), None
patent: WO 98/41246 (1998-09-01), None
patent: WO 99/21589 (1999-05-01), None
patent: WO 00/21542 (2000-04-01), None
patent: WO 01/13922 (2001-03-01), None
patent: WO 01/16180 (2001-03-01), None
patent: WO 02/098307 (2002-12-01), None
Dannemann et al. (2007, Bone 40 :828-834).
Fulfaro et al. (1998, Pain 78:157-169).
Bohndorf, 1998, Eur. Radiol. 8:103-112.
Podworny et al., 1999, J. Rheumatol. 26 :1972-1982.
Teronen et al., 1999, Ann. N.Y. Acad. Sci. 878:453-465.
Boissier et al., 2000, Cancer Research 60:2949-2954.
McCawley et al., 2000, Mol. Med. Today 6:149-156.
Gschaidmeier et al., 2000, Ann. Oncol. 11 (Suppl. 42000):10-11.
H. Fleisch, “The Use of Bisphosphonates in Osteoporosis” The British Journal of Clinical Practice, 48(6):323-326 (Nov./Dec. 1994).
LC Williams et al., “Update on Systemic Glucocorticosteriods in Dermatology” Dermatologic Clinics, 19(1):63-77 (Jan. 2001).
Manolagas, Stavros C., “Birth and Death of Bone Cells: Basic Regulatory Mechanisms and Implications for the Pathogenesis and Treatment of Osteoporosis,” (2000)Endocrine Reviews, 21(2):115-137.
Daluiski et al. Bone morphogenetic protein-3 is a negative regulator of bone density. Nature Genetics, vol. 27 pp. 84-88, 2001.
Little David Graham
Smith Nicholas Charles
Bozicevic Field & Francis LLP
Francis Carol L.
Kemmerer Elizabeth C.
The Royal Alexandra Hospital for Children
LandOfFree
Drug for the treatment of osteonecrosis and for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Drug for the treatment of osteonecrosis and for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Drug for the treatment of osteonecrosis and for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3929389